Launch of Phase 1 Clinical Trial for HOPO 14-1

HOPO Therapeutics is pleased to announce that SRI International has commenced a Phase 1 clinical trial for HOPO 14-1, with funding from the National Institute of Allergy and Infectious Disease. The open label study will assess safety, tolerability, pharmacokinetics, and excretion in 42 healthy participants, and is being conducted at SRI’s Plymouth, Michican facility. Coverage from the BBC and from National Geographic

We are thrilled to see the progression of our lead compound to into clinical development, passing a major milestone in our mission to develop novel and accessible treatments for life-threatening heavy metal toxicity. For more information about the trial, please visit https://clinicaltrials.gov/ct2/show/NCT05628961